LEDDA, ANDREA FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 677
EU - Europa 563
AS - Asia 196
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 1.442
Nazione #
US - Stati Uniti d'America 674
SE - Svezia 229
CN - Cina 146
IE - Irlanda 140
DE - Germania 66
TR - Turchia 43
UA - Ucraina 40
GB - Regno Unito 31
IT - Italia 21
FR - Francia 11
BE - Belgio 8
PL - Polonia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CZ - Repubblica Ceca 4
RU - Federazione Russa 3
AU - Australia 2
GR - Grecia 2
IN - India 2
SG - Singapore 2
CA - Canada 1
DO - Repubblica Dominicana 1
ES - Italia 1
FI - Finlandia 1
IR - Iran 1
JM - Giamaica 1
KR - Corea 1
RO - Romania 1
SA - Arabia Saudita 1
Totale 1.442
Città #
Chandler 169
Jacksonville 148
Dublin 140
Ann Arbor 56
Izmir 43
Nanjing 43
Ashburn 28
Bremen 20
Lawrence 20
Princeton 20
Woodbridge 20
Wilmington 19
Beijing 17
Boardman 15
Shanghai 13
Kunming 12
New York 12
Nanchang 11
Verona 10
Norwalk 9
Brussels 8
Falls Church 8
Mountain View 8
Shenyang 8
Tianjin 8
Milan 7
Hebei 6
Zhengzhou 6
Jiaxing 4
Ningbo 4
Olomouc 4
Hangzhou 3
Houston 3
San Mateo 3
Andover 2
Istra 2
Jinan 2
Los Angeles 2
Pune 2
Taizhou 2
Tappahannock 2
Thessaloniki 2
Changchun 1
Changsha 1
Chengdu 1
Chongqing 1
Des Moines 1
Fuzhou 1
Helsinki 1
Kazan 1
Kingston 1
Oviedo 1
Roanoke 1
Rome 1
Santo Domingo 1
Singapore 1
Surrey 1
Wenzhou 1
Totale 937
Nome #
Improvement of diabetic microangiopathy with Pycnogenol®: A prospective, controlled study 92
Treatment of ankle sprain in patients with vascular diseases of the lower limbs 92
Screening nelle farmacia: documento e linee guida 2008 86
LINFAVENIX: improvement of signs and symptoms of chronic venous insufficiency and microangiopathy 81
Vorbeugung von grippalen infekten mit colostrum 1 79
Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol®: A prospective, controlled study 77
Venoruton® vs Daflon®: Evaluation of effects on quality of life in chronic venous insufficiency 77
Rapid relief of signs/symptoms in chronic venous microangiopathy with Pycnogenol®: A prospective, controlled study 74
Daily consumption of reliv glucaffect™ for 8 weeks significantly lowered blood glucose and body weight in 50 subjects 73
Topical heparin: New observations 72
Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with pycnogenol 70
Lady Prelox® improves sexual function in post-menopausal women 70
Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects 69
Microcirculatory effects of Viatromb® spray gel heparin in chronic venous insufficiency: Evaluation of TcPO2 and PCO2 - A product evaluation study 69
Circulating endothelial cells in venous blood as a marker of endothelial damage in chronic venous insufficiency: Improvement with Venoruton 69
Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol® 69
Evaluation of the effects of supplementation with Pycnogenol® on fitness in normal subjects with the Army Physical Fitness Test and in performances of athletes in the 100-minute triathlon 68
Cramps and muscular pain: Prevention with Pycnogenol (R) in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy 67
Fingerprints and cardiovascular risk. The San Valentino fingerprint vascular screening project (SanVal/FP) 66
Pycnogenol® may alleviate adverse effects in oncologic treatment 54
Totale 1.474
Categoria #
all - tutte 4.762
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.762


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020178 44 5 24 2 1 22 26 0 22 8 2 22
2020/2021190 3 20 4 22 20 20 26 0 8 25 23 19
2021/2022302 24 4 133 25 20 9 14 7 7 6 12 41
2022/2023457 24 40 0 66 53 44 0 24 185 1 8 12
2023/202490 17 4 11 1 7 18 9 10 0 2 2 9
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 1.474